Testicular Yolk Sac Tumor Overview

Save information for later
Sign Up

Learn About Testicular Yolk Sac Tumor

What is the definition of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor is a subtype of testicular cancer that most commonly occurs in the testicles of young and middle-age men. While the exact cause is not well understood, some risk factors have been determined, such as undescended testicle, abnormal testicle development, smoking, exposure to some chemicals, family history of testicular cancer, HIV infection, and Down syndrome.
What are the symptoms of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor may have no symptoms or appear as a painless mass in the testes. If symptoms occur, they may include discomfort or pain, or a sense of heaviness in the scrotum, lower back of abdominal pain, an enlarged testicle, or an overgrowth of male breast tissue. The cancer may spread to other parts of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Testicular Yolk Sac Tumor?
Treatment for testicular yolk sac cancer depends on how far the cancer has spread and includes surgery (removal of the testicle), radiation therapy, and chemotherapy. Testicular yolk sac cancer is highly treatable and has a high rate of success. Testicular cancer can be detected early by performing a monthly testicular self-examination.
Who are the top Testicular Yolk Sac Tumor Local Doctors?
Pedro T. Ramirez
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology

Tmh Physician Associates PLLC

6550 Fannin St, Suite 901, 
Houston, TX 
 (62.3 mi)
713-441-1026
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pedro Ramirez is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Ramirez and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy. Dr. Ramirez is currently accepting new patients.

Dr. Pamela T. Soliman
Gynecologic Oncology | Oncology
Dr. Pamela T. Soliman
Gynecologic Oncology | Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (62.2 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pamela Soliman is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Soliman and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Pseudomyxoma Peritonei, Hysterectomy, and Oophorectomy. Dr. Soliman is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Anil K. Sood
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Dr. Anil K. Sood
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (62.2 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anil Sood is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Sood and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Endoscopy, and Oophorectomy.

View All Doctors
What are the latest Testicular Yolk Sac Tumor Clinical Trials?
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study is a first-in-human (FIH) Phase 1 study of BGB-B2033 to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of the BGB-B2033 in participants with advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors, non-dysgerminomas, or glypican-3 (GPC3)-positi...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Who is this study for: Patients with Tumor, Teratoma
Enrollment Status: Recruiting
Publish Date: February 13, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3

Summary: This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the gro...

View All Clinical Trials